Phio Pharmaceuticals - Intratumoral Neoadjuvant Therapy With Self-Delivering RNAi
Llamada en conferencia Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp Conference call will be held on 12-jun-2020. During the earnings conference call's session Phio Pharmaceuticals Corp will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Phio Pharmaceuticals Corp for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
RXi Pharmaceuticals Corporation ("RXi," "we," "our" or the "Company") is a clinical-stage RNAi company developing innovative therapeutics in dermatology and ophthalmology that address significant unmet medical needs. Our development programs are based on our proprietary self-delivering RNAi (sd-rxRNA®) platform and Samcyprone(TM), a topical immunomodulator. Our clinical development programs include, but are not limited to, RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone(TM) for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. In addition to these clinical programs, we have a pipeline of discovery and preclinical product candidates in our core therapeutic areas, as well as in other areas of interest.Leer más Llamada en conferencia